Fusion Pharmaceuticals announced that the first patient has been dosed in the Phase 1 study evaluating FPI-2059. FPI-2059 is a small molecule targeted alpha therapy designed to deliver actinium-225 to tumor sites expressing neurotensin receptor 1, a protein that is overexpressed in gastrointestinal, prostate, pancreatic ductal adenocarcinoma and multiple other cancers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FUSN:
- Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates
- Fusion Pharmaceuticals reports Q4 EPS (55c), consensus (56c)
- Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fusion Pharmaceuticals jumps 39% after buying prostate cancer detection assets
- Fusion Pharmaceuticals to resume trading at 4:35 pm ET